International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

Unveiling Psoriasis: A Comprehensive Examination of Etiology, Pathophysiology, Clinical, Presentation, and Management Strategies

[1]Priyanka Narode*, [2]Waghmare S.U, [3]Pravin akolkar, [4]Sanskruti Wagh, [5]Prasad Shelke, [6]Vaishnavi Borhade

[1,4,5,6]UG Scholar of Rashtriya College of Pharmacy Hatnoor,Tq.Kannad Dist.Chh.Sambhaji Nagar Maharashtra, India-431103.

*[*2,3] Assistant Professor of Rashtriya College of Pharmacy Hatnoor, Tq.Kannad Dist. Chh.Sambhaji Nagar Maharashtra, India -431103.*

Date of Submission: 10-06-2024 Date of Acceptance: 20-06-2024

ABSTRACT:
Psoriasis is a chronic, autoimmune and non communicable inflammatory disease Genetically Determined common dermatologicaldisorder which Affects skin, nails, joints and Has various systemic Associations. Over the last fifteen years, advances in ourknowledge of the path physiology of psoriasis have led to the development of highly focused and efficacious treatments. OfferingbasicunderstandingoftheIL-23/Th17axis-drivenpathphysiologyofchronicinflammatorydisorders·AntigenTh1,Th2,andTh17cells are differentiated from naïve T cells by presenting cells and secrete cytokines such as IFN-a, TNF-a, IL-2, IL-12, and IL-23,which are linked to the pathophysiology of psoriasis. The treatments that are already on the market only manage the disease'ssymptoms; a full cure is not yet possible. One has been reviewed in this project. Now that the immunological etiology is betterunderstood,thegoaloftherapyhaschangedtomorefocused,immunologicallyguidedintervention.Aerosol-containingmicrospheresmayoffernewavenuesforpsoriasistreatment.We'lltalkaboutcutting-edgebiologicsandmoderntherapymodalitiesinthis reviewofPsoriasis.

KEYWORDS:
Psoriasis,Etiology,Pathophysiology,Clinical Presentation,anddosageform.

I. INTRODUCTION:

Psoriasis is a long-term, non-communicable, inflammatory skin and joint disease caused by the immune system. The name"psoriasis" is derived from the Greek "psora," which means "itching," and "iasis," which means "condition." The condition ispresent in 2% of the world's population, with developed nations having a greater prevalence of 4.6%.[34]It is typified by distinctlydefined scaly, red, coin-sized skin lesions, which are typically found on the hands, feet, knees, elbows, and scalp. Among thesymptoms include stinging, pain, discomfort, and itching. In rare cases, the entire skin surface of the body may be impacted.Auspitz's Sign and the Koebner phenomena are indicators of psoriasis.[1] Skin disease is one among Chronic disease and also oneof the Eight Dreadful diseases. The disease psoriasis comes under the leprosy. Psoriasis is one of the most common DermatologicDisorder and a chronic skin disorder of present day .Majority of skin diseases are categorized as Major and Minor skin diseasesand are detailed under Skin Disease. [2] Psoriasis is a prevalent, recurring, inflammatory skin disease that is characterized by dry,erythematous, and rounded scaling. Patches with varying widths, coated in lamellar scales that are either silvery white or grayishwhite. Multifactorial disease is psoriasis. Infection, medication, trauma, and other things are triggers. Worldwide, 3% of peoplesuffer with psoriasis. The incidence of psoriasis in India ranges from 0.44 to 2.88%. For psoriasis, there is currently no effectivemedicationavailable.Plaquepsoriasisisatype ofPsoriasisthatpresentsassilveryscalylesions,wellDefinederythematouspapulesordry,brittle,silveryorGrayishwhiteplaque.[3]Psoriasisisaninflammatorydiseas eaffectingmultiplesystems,primarilytheskinand joints. In addition to the physical components of the condition, psoriasis affects sufferers emotionally and psychologically, impacting social functioning and interpersonal relationships. It has a bimodal age of onset (16 to 22 and 57 to 60 years), and it affects both sexes equally. Multifactorial etiology includes both dysregulated inflammation

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

and genetic relationships. Numerous conditions, including cancer and cardiovascular disease, are associated with psoriasis, a systemic inflammatory disease. Treatment may not always begin immediately, depending on the severity of the sickness. A skin biopsy is rarely necessary because the diagnosis is mostly clinical. There are various types of psoriasis, but chronic plaque psoriasis is the most prevalent variety, affecting 80% to 90% of the population. Thehallmarks of classic plaque psoriasis are well-defined, symmetrical, erythematous plaques with a silvery scale covering them.Plaques can appear anywhere on the body, but the scalp, trunk, buttocks, and extremities are where they are most frequentlyencountere.Patientsmayexhibitnailinvolvement,eveintheabsenceofconcurrentplaquedevelopment.Lesionsthatareactivelygrowingmayitchorhurt. Psoriasiscanoccasionallyshowupasanisomorphicresponseinsituationsofprolongedstressordamage,where new lesions develop on skin that was previously normal (a condition known as Koebner's phenomenon).Topical treatments,such as corticosteroids, vitamin D3 analogs, and combination products, constitute the mainstay of treatment for mild to severeillnessesintraditional medicine.Thetraditionalmedicalsystemdoesnotoffer agood psoriasistreatment.[4][35]

TypeofPsoriasis	**Characteristics**	**Image**
1)PlaquePsoriasis	Most common formDry,raised,redlesionItchyand painful Anywhereonbodyincludinggenitalsandinsidemouth	
2)NailPsoriasis	Fingernails and toenailsPitting, abnormal growth,discoloration Severecasescausenailtocrumble	
3)GuttatePsoriasis	Primarily young and smallchild Triggered by bacterial infectionSmallwater dropletshape.	
4)InversePsoriasis	Skin,armpits,groin,underbreasts,aroundgenitals Smooth patches of red inflamedskin Madeworseby sweating	
5)PostularPsoriasis	Uncommonform Widespreadpatchesonhands,feet,fingertips Developsquicklyfrompusfilledblisters	
6) ErythrodermicPsoriasis	Least common formRed,peelingrash. Itchesandburnsintensely	

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

7)Psoriaticarthritis	Inflameditchyskin Painful swollen jointsStiffnessandprogressivejointdamage	

TableNo.1:-Type of Psoriasis

Etiology:

It's unclear what caused this persistent psoriasis. The most frequent etiological factor for psoriasis is stress, and individuals withlong-term conditions like Crohn's disease are more susceptible to the condition. Beta-blockers, lithium, synthetic antimalarials, nonsteroidal anti-inflammatory medications (NSAIDs), and tetracyclines appear to have a substantial causative association with psoriasis. Patients who suffer from the severe kind of this illness are more likely to have cardiac comorbidities. The more recent target-based medicines are the main topic of this review.

Bothmenandwomencangetpsoriasis,butwomenandthosewithafamilyhistoryaremorelikelytodevelopitearly.Theonsetagedisplaysabimodaldistribution,withwomenpeaking10yearssoonerandmenpeaking30–39and60–69 years older, respectively. Psoriasis is thought to affect 60 million individuals globally; prevalence varies by nation, rangingfrom 0.05% in Taiwan to 1.88% in Australia.3,4 Older populations and affluent locations seem to have higher incidence of it.3. Itaffects 1.52%ofthegeneralpopulation in theUK.[5]

Pathophysiology

The chronic inflammatory disease psoriasis is typified by immune cell activation and the release of several cytokines. Stress signals are produced by the interaction of antigens with dendritic cells, which activates keratinocytes and finally T lymphocytes. These T cells undergo differentiation into Th1 and Th17 effector cells, which release cytokines including IL-17, IL-22, TNF-a, and IFN-a. These cytokines cause keratinocytes to proliferate excessively and aid in the development of psoriatic plaques. [36] Th17 cell development and the upregulation of IL-17 and IL-22 expression are both significantly aided by IL-23. Furthermore, vascular endothelial growth factor is highly expressed in psoriatic plaques, which promotes angiogenesis and the characteristic bleeding spots that disappear with excision. IL-8 exacerbates the inflammatory response by contributing to the buildup of neutrophils in the skin. [6]



International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

Fig1: Pathology of Psoriasis



Fig.2: Clinical Management of Psoriasis

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

Clinical presentation:

There are several ways that psoriasis can manifest: Plaque psoriasis is the most common type of psoriasis, affecting mainly the scalp, extensor surfaces (knees and elbows), trunk, and well-defined salmon pink plaques with silvery-white scale.The plaques are usually distributed symmetrically. Where scales have been removed, bleeding spots may be observed (Auspitz sign). The axillae, submammary, and vaginal regions are susceptible to flexural psoriasis, which usually appears without much scaling. The hallmark of guttate psoriasis is acute symmetrical eruptions of drop-like papules or plaques, usually but not always affecting the trunk and limbs. Streptococcal infection is usually but not always the cause of this condition.[37] Patients with guttate psoriasis may later develop plaque psoriasis. Erythroderma, a widespread erythematous rash caused by severe uncontrolled illness, is a rare but potentially fatal consequence of psoriasis. Potential complications include hypothermia, infection, acute renal injury, and high-output heart failure.The occurrence of psoriasis in traumatized skin areas is known as the Koebner phenomenon. Up to 50% of patients may have nailproblems, which can show up as subungual hyperkeratosis, oil patches, onycholysis (when the nail plate separates from the nailbed), nailpitting, and dystrophy.[8]There aresome herbal formulation are available for the treatment of psoriasis.Herbal dosage form that can effectively used for the management of psoriasis. [38]

TreatmentForPsoriasis:

1) Soliddosage form

- **Corticosteroids** –They are the most frequently prescribed medications for treating mild to moderate psoriasis. They slowcell turnover by suppressing the immune system, which reduces inflammation and itching. Low-potency corticosteroidointmentsusually recommended for sensitive areas such as face or skin folds, and for treating widespread patches ofdamaged skin. Adverse effects seen are thinning of the skin, telangiectasia and systemic side effects such as diabetes,hypertension and HPA suppression. Some of the corticosteroids used are clobetasol propionate 0.05%, amcinonide 0.1%,betamethasone dipropionate, betamethasone valerate as 0.1%, 0.12% and 1%, halcinonide 0.1%, desoximetasone 0.25%and mometasonefuroate.[7]
- **VitaminDAnalogues** – VitaminDanalogues(calcitriolandcallipering)havee mergedasimportantalternativestotopicalcorticostero ids for the long-term therapy of psoriasis. They bind to cytoplasmic Vitamin D Receptor then translocate intothe nucleus, where they bind to nuclear receptor and commence the transcription of vitamin D responsive genes. Thesetranscription proteins then regulate cell differentiation and down regulate cell proliferation and inflammatory processesassociatedwiththiscondition.Theyareconsi deredasafealternative,despitecausingperi-lesionalirritationanderythema.They may rarely increase serum and urine calcium levels, so the total concentration per week should not exceed 100 gm.Calcitriol is more potent analogue but calcipotriene is most established one. Calcipotriene has shown to affect calciumhomeostasistoverylesserextent.[8]Mosttrials haveshownthatcombinationtreatmentofvitaminDan dcorticosteroidwasusuallymoreeffectivethan monotherapy with eitherusedalone.[9]
- **Anthralin (Dithranol)** – It is derived from the Araroba tree found in South America. It induces reactive oxygen speciesrelease, which has an inhibitory effect on hyper proliferating keratinocytes and the transformation of leucocytes. It is usedtopically to the scalp at escalating dosages (0.1% to 3%). It can be used on an inpatient basis; additionally, short-contacttherapy for outpatients are already offered. Adverse effects are discoloration of the hair and skin irritation. [10]A smallnumber of studies have demonstrated that using anthralin in conjunction with topical treatments or phototherapy canenhanceresponse.
- **Coal Tar** - One of the earliest topical treatments for psoriasis, it can be used alone or in conjunction with systemicmedications, phototherapy, and other topical therapies. Coal tar's polycyclic aromatic hydrocarbons increase the skin'ssensitivity to UV radiation. [11] Still the exact mechanism of action is unclear. Coal tar has anti-inflammatory, anti-proliferative and strong anti-pruritic properties. [12] It is less cooperative due to its disagreeable odor, staining abilities, andpotential for mutagenesis effects. Certain non-staining and washable formulations, such as lotions and shampoos, areofferedeitherbythemselvesorin conjunctionwith additionalactiveingredients to improve compliance[13].
- **Retinoids-** Inchronicplaquepsoriasis,oralretinoidsareprima

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

rilyusedasmaintenancetherapy.Theyarealsospecificallyutilized in pustular psoriasis and, though they may be less effective in erythrodermic psoriasis, they can be used in bothconditions. [14]It is thought to reduce inflammation and restore normal DNA activity in skin cells. The recommended dailydosage is between 10-50 mg, which can be used as a single dose or in divided doses. Adverse effects of retinoids are amajor concern and can include skin irritation, increased sensitivity to sunlight, xerosis, pruritus, cheilitis, alopecia,xerostomia, dyslipidaemia, deranged liver enzymes and teratogenicity. A low dose regimen is also an option where up to25mg perday isgiven to minimizemucocutaneousside effects.[15,16]

- **Methotrexate** – This is an immuno suppressive, antimetabolite and is one of the most effective and relatively low-costtherapy to treat psoriasis. Methotrexate is dihydrofolate reductase inhibitor and folic acid is supplemented to decreasetoxicityofthedrug.It isusuallygivenasasingleoraldoseperweek.Adverseeffectscanbemyelosuppression,mucositis,hepatotoxicity,pulmonarytoxicity,nephrotoxicity,neurotoxicity,gastrointestinalupset,nausea,oligospermia,andteratogenicity.[15][16]Longterm therapy can causehepatotoxicity thatcan progressto liverfibrosis.[17]
- **Cyclosporine** – It is very effective oral treatment option to treat moderate-to-severe psoriasis. It binds to cyclophilin,inhibits calcineurin, and hence induces immunosuppression through preventing down-stream T-cell activation. It inhibitsthe activation of nuclear factor of activated T-cells (NFAT) & further inhibition of gene transcription of IL-2 by T cells. [18]Adverse effects can be nephrotoxicity, hepatotoxicity, hypertension, diabetes mellitus, neurotoxicity, hirsutism, increasedrisk ofinfection and an increasein non-melanomaskincancerswith long-termuse.[19]

Advantagesofsoliddosage form:

1. Givingthe tablets is asimple process.
2. Thisdoseformismoresteady.
3. Theyaresimplertoadminister.
4. Theycontinuetomaintaindose precision.
5. Thisisthecosteffectivedosageform.
6. They are the lightest and most compact dosage forms available.

Disadvantage ofsoliddosage form:

1. Poorbioavailabilityofpoorlysolubledrugsorpoorlyabsorbable drugs.
2. Somedrugs maycauselocalirritationeffectharmGITmucosa.
3. Certain medications might not compress well in tablets.
4. Swallowing difficulties in certain patients, including younger and older adults.
5. Intravenous or intramuscular injections are more effective in emergency situations,
6. Firstpass metabolism
7. Bittertaste
8. Hepaticfirstpassmetabolism[39]

2) **Phototherapy:** It is advised for people whose psoriasis plaques cover 20% or more of their body surface or for those whosecondition does not improve with topical treatments. Although the precise mechanism is unknown, it is thought to causekeratinocytes to undergo apoptosis in addition to increased IL-10 transcription and expression.With skin clearance observedinover80%ofpatients,ithasdemonstrategoodsuccessrate[20].UVB radiation in combination with coal tar (Goeckerman therapy) or anthralin (Ingram regimen) has been demonstrated to be effective in patients with moderate-to-severe psoriasis. Systemic psoralens (PUVA therapy) and ultraviolet A radiation (UVA) have been found to work well together to remove skin lesions; however, both of these therapies must be sustained and raise the risk of skin cancer.[21]Broadband UVB treatment is less effective than narrowband UVB therapy (311-313 nm). Once the skin starts to recover, itmay just need to be applied twice a week for maintenance. It can result in burns that are more severe and stay longer. Given inconjunctionwithtopical tazarotene,it isasaferand almostaseffectivesubstitute forPUVA.[22][23]

Advantages:

1. Diminish the psoriasis's look.
2. Eczemasymptoms.
3. Safeinchild.

Adverseeffects:

1. Redness
2. Itching
3. Dryskin
4. Wrinkledskin
5. Freckles
6. Skin cancer

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

7. Expensive
8. Doesnotapplyany partofbody

3) **NewDrugTargets:**Overthelasttwentyyears,Innovative biologics have been produced as a result of a shift in emphasis toward treating diseases. More selective and immunologically targeted action is the aim of these medicines, perhaps with fewer side effects than with traditional therapyAs this is an era of target-based therapies, thedevelopmentofthenew drugsand biologicsarebased onfollowing strategies:

1. Blockadeofinitialcytokinerelease andAPCmigration
2. TargetingactivatedTcellsandpreventfurtherT-cellactivationandimmunologicalcascade
3. Inhibitionofcytokines suchasTNFa
4. InhibitionofdifferentiationoftheactivatedTcells intoTh1andTh17cells
5. InhibitionofcytokineslikeIL-17anditsinteractionwiththereceptor.

Biologics: Thesearethemolecules,whicharedevelopedfortarget-basedtherapy.Theyhaveamorepreciseactionand sideeffectsare thought to be less as compared to the broad traditional therapies. These agents act on the varied steps of the pathogenesis of thepsoriasis and aredivided intovariousgroupson the basisoftheirmode ofaction.[40]

i. **Anti TNF-α agents:** These are molecules, which act on the tumor necrosis factor (TNF-a) or by blocking the TNF-areceptors.Psoriaticplaquescontainahighamountofof TNF-awhichisastrongpro-inflammatorycytokineandisoneoftheprime mediators in the development of inflammation in psoriasis. TNF-a stimulates the production of other cytokines,activates other immune cells and increases its own secretion and also induces the adhesion of molecules by keratinocytesand further increases the recruitment of immune cells.38 Hence, anti TNF-a agents binds to TNF-a, captures them andfinally neutralizes them or blocks the TNF-a receptor on the keratinocytes and other immune cells to shut down theimmunologicalcascade.Adverseeffectsinclude haematologicalandsolidorgancancers,autoantibodydevelopment,drug-induced lupus erythematosus, infusion and injection site responses, infections, especially recurrence of TB, and liverfunctionabnormalities.

ii. **IL-23ANDIL-12Inhibitors:**Twokeyplayersinthepathophysiologyofpsoriasisare Cells andIL-23.Immunecellsarestimulated by IL-23, which also boosts their survival and multiplication. Th17 cell growth and maintenance are aided bydendritic cells and macrophages, which also produce more IL-23. These IL-23 and IL-12 inhibitors, such as as tekinumaband apilimod, stop the immunological cascade by blocking the subunits of IL-23 and IL-12.Nasopharyngitis, headaches,diarrhoea, upper respiratory tract infections, and in rare cases, neutropenia, Crohn's disease, etc., are examples of adverseeffects.

iii. **Fusion Protein Inhibitor:** The medication in this class with FDA approval is alefcept. It is a human fusion protein and itbinds to CD2 on T cells. It has dual mechanism of action, it blocks the interaction between the leukocyte-function-associatedantigen(LFA)-3andCD2onTcellsandhenceblockstheactivation andproliferationoftheimmuneCD4+andCD8+ T cells. It also induces apoptosis of activated memory T cell.58 Dosage is 15 mg IM or 7.5 mg IV per week andadverse effectscanbelymphopenia,skincancers,lymphomas,hepatotoxicity.

iv. **Janus Kinase Inhibitor:** The FDA approved tofacitinib, an oral selective Janus kinase inhibitor, to treat rheumatoidarthritis (RA). However, more recently, it was investigated and is currently in phase 3 trials for the treatment of psoriasis.Tofacitinib selectively Inhibits signaling by blocking JAK3 and JAK1 with more selectivity than the receptors thatfunctions through JAK2. JAK1 inhibition reduces the pro-inflammatory cytokines, like IL-6 and INF-alfa, thataresignalled.Furthermore,itsuppressestheexpressionoftheIL-23receptor,whichaffectsIL-23signalingand,asaresult,immune celldifferentiation, includingTh17 celldifferentiation.

v. **Phosphodiesterase-4 Inhibitor:** Cyclic adenosine monophosphate an intracellular second messenger that regulates avarious ofpro-andanti-inflammatorymediators,ishydrolysed bytheenzymephosphodiesterase4TheFDAhasapprovedthe oral medication apremilast for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It worksintracellularlytoregulateinflammatoryme

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

diatorsbyincreasingthecAMPlevelsinthecells.Adverseeffectsarediarrhea,nausea,upperrespiratory infections, and headacheand weightloss.[24]

Advantages:
1. Producetargetedtherapy.
2. Hightherapeuticaction.
3. Fewerside effects.

Disadvantage:
1. Disorders of the central nervous system
2. Cardiac issues
3. Lupus-like syndrome
4. Centralnervoussystemreactionsymptoms thatcanoccuraresuddenvisionproblems oranynewnumbness ortingling
5. Upperrespiratoryinfections
6. Pneumonia
7. Urinarytractinfections
8. Skininfections
9. Fatigue
10. Fever
11. Chills
12. Weakness.
13. Nausea, vomiting
14. Diarrhea

5) Photodynamic therapy: A type of phototherapy called photodynamic therapy (PDT) is one of the most promising approachestotreatingpsoriaticlesions.Itentailsapplyingacell-targetingphotosensitizingcompoundeitherlocallyorsystemically,followedby selectively shining visible light on the lesion. Nevertheless, there is a limit to how well clinically integrated photosensitizersmay treat psoriasis.

Advantages:
1. Helpremovesun-damagedprecancerous.
2. Remove.Sundamage.
3. Removefinelines.
4. Improvepigmentation[41]

Disadvantage[25]
1. Aspain
2. Burning sensations
3. Photosensitivityaftertreatment
4. Treatmentefficacydependsonaccuratelightdeliverytotheinfectedskin.
5. Tissueoxygenationiscrucialtothephotodynamic effect

6) Ointment: Robust topical corticosteroid betamethasone valerate 0.1% ointment applied in the morning and calcitriol 3 µg g-1 ointment applied in the evening (n = 9); or betamethasone valerate ointment applied in the morning and evening (n = 10). Six weeks were allotted to treatment. The combined drug was at least as effective as betamethasone alone, according to the three efficacy criteria that were examined. The average score for global improvement (26). According to trial endpoint data, 60% of patients receiving betamethasone daily and 78% of patients taking calcitriol/betamethasone showed significant improvement, or better. It offers topical treatment.[42]

AdvantagesofOintment:
1. Ointments are simpler to apply than large liquid dose forms.
2. Compared to liquid dose forms, they are chemically more stable.
3. They make it easier to apply the medication specifically to the affected body part and prevent the drug from getting into other parts of the body.
4. They are appropriate for people who have trouble taking their medications orally or parenterally.

Disadvantage:
1. Skinirritation
2. Burning and itchingsensation
3. Atrophy
4. Striae
5. Rosacea
6. Perioraldermatitis
7. Acne&purpura

7) Cream: The first and only PDE4 inhibitor topical that has been approved for the treatment of both plaque and intertriginous psoriasis Effective drug with no time limits on use that is authorized for mild, moderate, and severe plaque psoriasis. All affected areas of the body see a reduction in irritation and a prompt removal of plaque. ZORYVE is advised as a topical treatment for plaque psoriasis, including intertriginous regions, in patients 12 years of age and above. [27]

Advantages:
1. Injuredarea can be dried quicklybycreamsthanothersemi-solidpreparations.
2. Non-irritatingwhenappliedtotheskin.
3. Easilywaterwashable.Easytowipeaway.
4. Less greasycomparedto ointment.[43]

Disadvantages:
1. Skindamage,
2. Skinthinning
3. Changes in pigmentation
4. Easybruising

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

5. Stretchmarks
6. Redness
7. Irritation
8. Itching
9. Dilatedsurface bloodvessels

8) Foam:

Enstilar®(calcipotrieneandbetamethasonedipropionate0.005%)Foamisaprescriptionmedicationappliedtopicallytoindividuals 12 years of age and above to treat plaque psoriasis. The safety and efficacy of Enstilar Foam in children younger than12 years old is unknown. Only topical application of Enstilar Foam is permitted. Avoid getting Enstilar Foam in your eyes, mouth,orvagina. StellarFoamshouldnotbeappliedtothe face,groin,armpits,orareaswhere atrophyhas resultedinskinthinning.(28)

Advantages:

1. MoistureResistance.
2. Sustainability.
3. Cost-Effectiveness.
4. EasyCustomization

Disadvantages:

1. Sitereactions
2. Pruritus
3. Skinirritation
4. Burning
5. Stingingsensation
6. Dryskin
7. Erythema
8. Rash
9. Dermatitis
10. Psoriasisaggravated
11. Photosensitivity
12. Hypersensitivityreactions
13. Angioedema
14. Facialoedema. [29]

9) Aerosol: Products that rely on compressed or liquefied gas's force to release their contents from a container are referred to asaerosols. The products can be sprayed finely, foamed, or streamed semi-solid. Aerosols are also defined as preparations used fortopical application that comprise therapeutically active substances dissolved or emulsified in a propellant or mixture of propellantand solvent [30]. When compared to traditional topical formulations, it offers numerous benefits, including consistent drugdistribution and dosage, enhanced bioavailability, reduced irritability, continuous drug release, and rapid wound healing throughmoisturecontrol.Sprays thatformfilmsare madeupofexcipientsandpolymers.Thatstrengthenthe stabilityofactive substancesandincreasethequalitiesofpreparations[31].

Depending on the intended usage and application location, an aerosol's formulation may change. Compared to OSD, brief ascosolformulationsarethemosteffectivenon-dispersibledrugdeliverysystem(NDDS)fordeliveringactivepharmaceuticalingredients(APT) to the systemic circulation and achieving faster local action. Since this dose type is given topically, it has no effect on thebody's primary organs. It has been determined that the sensitivity to locally applied area is either negligible or absent. Itsbioavailabilityissuperiorthan thatoftheotherdosetype.&theintended pharmacologicaloutcome[32].

Advantage'sofAerosol:

1. Dosecanbedeliveredwithoutcontaminationwithoutcontaminationofentireproduct.
2. Sterilitycanbe maintainedifrequired.
3. Noneed ofany mechanicalmeansforapplication.
4. Easyto usewith betterpatientcompliance.
5. Medicationcandeliveredirectlyatthesiteofactionindesireformi.e.Spray,Foametc.
6. Entire little skin area covered.
7. Not visible or perceptible after application.
8. Refraining from using first pass metabolism.
9. Preventintra-andinter-patientfluctuations inmedicationlevels.
10. Possibilityofmoretargetedmedicinedeliverytoa particularlocation.
11. Asizableapplicabilityspectrum.
12. Preventinggastrointestinalincongruity.[33]

DisadvantageofAerosol:

1. Expensive
2. Sometimeproduceallergicreactions.
3. Difficulttodiscardemptycontainer.

Advantages ofAerosoloverotherdosageform:

AerosolDosageForm	Otherdosageforms

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

i.Because the contents are tightly packed and made ofrobust materials, they may be removed from the boxwitheasewithoutcontaminatingorexposingthe remainingmaterial.	i. Because the packaging material is so thin, thereis a greater possibility of contamination by handandminutebreaksin it.
ii. ItConvenienttoapplyandadministerwithou tthehelp ofothers.	ii. Itisnotveryconvenient,andassistancean d directionarerequired.
iii. Itprovideonsetofactionis quickly.	iii. Incontrast,OSDandotherdoseformsdon ot seemtoworkanyfaster.
iv. improved dispersion of APIs results in improved pharmacological activity in a shorter amount of time.	iv. Dispersion takes longer to absorb than absorption(poorefficacyofthepharmacokinetic
	ADMEprocess). It therefore shows less pharmacologicalimpactincontrast.
v. Becozof closedpackaging,aerosolandAPISdonotcome intodirecttouch.	v. Packagingdoes not a thinandblistered
vi.Whentakenorally,theaerosolformulationanditsD DSlimit medication inactivation and degradation broughtonbythestomachorintestines'enzymaticacti onor pH..	vi. Directinteractionwithfoodparticleenzy mesusuallyresultsin inactivation.
vii. It enhances medication absorption through hepatic metabolism and inhibits first-pass metabolism.	vii. Firstpassmetabolismindicatesthatlessm edicationgoesthroughtheADMEpathway.
viii. Propellers don't contain any moisture, thus it's possible to stop the hydrolysis of used excipients and APIs.	viii. Itexhibitscontaminationandlacksspecif icity.
ix. Evenwiththevalveopened,microorganism scannotenter,providingsterilitytoAPIs.	ix. WhenmedicineexcipientsandAPIsaree xposedtohighlevelsofmoisturecontact,they hydrolyze.
x. It maintains control over the valve assembly; the released substance's physical attributes and particle size may increase the efficacy of a drug.	x. Compared to that, no such sterile
xi. Topicalaerosolspraycanhelpminimizeinfl ammationandirritation.	xi.Notasirritatingasaerosol,butextremelyirritatin gintheeventofparenteralifadministeredimproperl y.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 3 May-June 2024, pp: 2161-2173 www.ijprajournal.com ISSN: 2456-4494

xii.Thequickestpropellantvolatilizationresultsinare juvenating and cooling effect, activating the sinuses,whichinturnpromotesbloodcapillariestowiden and musclestorelax,optimizingtheeffects oftheAPIs.	xii. EfficacyincreaseincaseofParenteralnoticaseofOSDS.

TableNo.2

II. CONCLUSION

The present investigation aimed to prepare and Evaluate novel aerosol containing drug in order to provide Long-term therapeuticactivity at the site of infection. This invention deals with pharmaceutical chemical compositions intended for topical application. The invention particularly concerns topical medication spray compositions, their application, and the films that are created during usage.Numerous illnesses may be treated using the formulations. Using topical spray formulations lessens the issue of skin irritation related to transdermal patches, lotion, cream, etc. Thisprojectdescribestargetbasedtherapiesforthetreatmentpsoriasis.

REFERENCE:

1) Sunildorga,savitaYadavPsoriasisinIndia:PrevalenceandpatternbyIndianJournalofdermatology,venereologyandleprology. Nov-Dec2010PMID:21079301DOI:10.4103/0378-6323.72443
2) AdrianaRendonandKnutSchäkelPsoriasisPathogenesisandTreatmentInternationalJournalofMolecularScienceMarch232019 pg no. 1475PMID:30909615. doi:10.3390/ijms20061475
3) SiddharthaDutta*,ShaliniChawla,SahilKumar.Psoriasis:AReviewofExistingTherapiesandRecentAdvancesinTreatmentJRationalPharmacotherResVolume 4 (Issue1):2018
4) Pooja P Thakre1*, Sourabh Deshmukh2 , Vinod Ade. A Case Study on Plaque Psoriasis with Ayurvedic ManagementInternational Journal of Ayurvedic Medicine Published 03-07-2020Vol. 11 No. 2 (2020): April - June2020DOI:https://doi.org/10.47552/ijam.v11i2.1449
5) Pooja P Thakre1*, Sourabh Deshmukh2 , Vinod Ade. A Case Study on Plaque Psoriasiswith Ayurvedic ManagementInternational Journal of Ayurvedic Medicine Published 03-07-2020Vol. 11 No. 2 (2020): April - June2020DOI:https://doi.org/10.47552/ijam.v11i2.1449
6) Sinimol T. Peethambaram Case Study AYURVEDIC MANAGEMENT OF PLAQUE PSORIASIS- A CASE STUDYInternational Journal of Ayurveda And Pharma Research ISSN: 2322 - 0902 (P)ISSN: 2322 - 0910 (O) | November 2019 |Vol7 | Issue11
7) AntonyRaharja,foundationyear-2doctor(academicfoundationprogramme),ASatveerKMahil,consultantdermatologist,Band Jonathan N Barker, professor of medical dermatologyC). Psoriasis: a brief overview MayPMC PubMed Central2021;21(3):170–173Doi: 10.7861/clinmed.2021-0257
8) AntonyRaharja,foundationyear-2doctor(academicfoundationprogramme),ASatveerKMahil,consultantdermatologist,Band Jonathan N Barker, professor of medical dermatologyC). Psoriasis: a brief overview May PMC PubMed Central2021;21(3):170–173 Doi: 10.7861/clinmed.2021-0257
9) Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C et al. Topicaltreatments for scalp psoriasis. PMCPubMed CentralCochrane Database of Systematic Reviews Feb2016:Art.No. CD009687. PMID: 26915340 PMCID:PMC8697570DOI:10.1002/14651858.CD009687.pub2
10) Kragballe K. Calcipotriol: a new drug for topical psoriasis treatment PMC PubMedPharmaco lToxicol Oct 1995 ;77(4):241-6.Doi:10.1111/j.1600-0773.1995.tb01020.x.
11) Mason AR, Mason J, Cork M, Dooley G, HancockH.Topicaltreatmentsforchronicplaquepsoriasis. PMC PubMedArticle,CochraneDatabaseofSystematicReviewsMarch2013:Art.No.:CD005028DOI:10.1002/14651858.CD005028.pub3
12) Dogra S, Kaur I. Childhood psoriasisPMC PubMed Article Indian J DermatolVenereolLeprol July -august 2010;76:357-65.Doi:10.4103/0378-6323.66580.
13) Thami GP, Sarkar R. Coal tar: Past, present

and future. PMC PubMed Article ClinExp Dermatol 27 march 2002;27:99-103.DOI:10.1046/j.1365-2230.2002.00995.x

14) DiezelW,GrunerS, AnhaltGJ. ATPasepositiveepidermalLangerhanscells:inhibitionof ATPasebyammoniumbituminosulfonate(Ichthyol)andpixlithanthracis.PMCPubMedArticleHautarztJan1992;43:22-4. PMID:1351891
15) NICE. Theassessmentandmanagementofpsoriasis. CG153.2012.[Accessed on August29,2017] Availablefromhttps://www.nice.org.uk/guidance/cg153.October2012.
16) KuijpersAL, VanDooren-Greebe JV, VandeKerkhofPC.FailureofcombinationtherapywithacitretinandcyclosporinAin3patientswitherythrodermicpsoriasis.PMCPubMedArticleDermatology1997;194:88-90.PMID:9031805DOI:10.1159/000246070
17) Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: arandomized,double-blind,placebo-controlledtrial.BritishJournalDermatolJuly2006;154:1169-74.DOI:10.1111/j.1365-2133.July 2006.07289.x
18) BrownellI,StroberBE.Folatewithmethotrexate:bigbenefit,questionablecost.BritishJournalDermatolJuly2007;157:213PMID:17578449 DOI:10.1111/j.1365-2133.2007.08005.x
19) LaharieD,TerrebonneE,VergniolJ,ChantelloupE,ChabrunE,CouzigouPetal.Theliverandmethotrexate.GastroenterolClinBiol Feb 2008;32:134-42. Doi:10.1016/j.gcb.2007.11.002.
20) Colombo MD, Cassano N, Bellia G. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose,duration,andoldandnewtreatmentapproaches.ScientificWorldJournal25July2013;13:1-11.PMCID:PMC3745987DOI:10.1155/2013/805705.
21) Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management ofpsoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditionalsystemicagents.JAmAcadDermatolSep 2009;61:451-85. PMID:19493586 DOI:10.1016/j.jaad.2009.03.027.
22) Camisa C. Psoriasis: a clinical update on diagnosis and new therapies. Cleve Clin J Med Feb 2000;67:105-113.PMID:10680277 DOI:10.3949/ccjm.67.2.105
23) GreavesMW, WeinsteinGD. Treatmentofpsoriasis.NEnglJMedMarch1995;332:581-8.PMID:7838193DOI:10.1056/NEJM199503023320907
24) Gordon PM, Diffey BL, Matthews JN, Fair PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVAphotochemotherapyforpsoriasis. JAmAcadDermatolNove1999;41:728-32.PMID:10534635DOI:10.1016/s0190-9622(99)70008-3
25) BehrensS,Grundmann-KollmannM,SchienerR,PeterRU,KerscherM. Combinationphototherapyofpsoriasiswithnarrow-bandUVBirradiationandtopicaltazarotenegel. J Am AcadDermatolMarch2000;42:493-5PMID:10688723DOI:10.1016/s0190-9622(00)90225-1
26) SiddharthaDutta*,ShaliniChawla,SahilKumar.Psoriasis:AReviewofExistingTherapiesandRecentAdvancesinTreatment.JRationalPharmacotherResVolume4(Issue1): October2018.
27) Sebastian Makuch , Mateusz Drozdz, AlicjaMakarec , Piotr Ziólkowski. An Update on Photodynamic Therapy of Psoriasis—Current Strategies and Nanotechnology as a Future Perspective. International Journal of Molecular Sciences August 2022 30;23(17):9845DOI:10.3390/ijms23179845.
28) LutzKowalzickNovel topical therapy for mild-to-moderate plaque psoriasis: Focus on calcitriol. Clinical, Cosmetic andInvestigationalDermatology. Sep 2009 16:2:153-9.Doi:10.2147/ccid.s5758.
29) Arcutis'Biotherapeutics.FDAApprovesArcutis'ZORYVE™(Roflumilast)Cream0.3%FortheTreatmentofPlaquePsoriasisinIndividualsAge12 and Older
30) TheLEOPharmalogo,LEOPharma,andEnstilarareregisteredtrademarksofLEOPharmaA/S. ©2021LEOPharmaInc.Allrights reserved.January 2021MAT-38267
31) AshishPathak,SarleshRajput.Areviewonmicrospheres:MethodsofpreparationandevaluationWorldJournalOfPharmacyandPharmaceuticalSciencesJune2012,Volume1, Issue 1-422-438.
32) Abd Kakhar Umar, Maria Butarbutar,

Sriwidodo Sriwidodo, and Nasrul Wathoni .Film-Forming Sprays for Topical DrugDelivery.DrugDesDevelTher.July2020; 14:2909–2925.doi:10.2147/DDDT.S256666

33) MAHENDRA PRATAP SWAIN1, MAUNAB PATRA, DR. MEENAKSHI PATNAIK. Excipients and itsvariationinpharmaceuticalAerosolformulation :AReview. InnovatInternationalJournalOfMedical&PharmaceuticalSciences,Nove2016;1(1)DOI:10.24018/10.24018/iijmps.2018.v1i1.22

34) Tejasavi Mahajan, Navdeep Singh, Kamya Goyal, Shammy Jindal, Vinay Pandit, M.S. Ashawat. Recent Updates on Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2022; 12(1):76-3. Doi no 10.52711/2231-5691.2022.00012

35) Navdeep Singh, Shivi Sondhi, Shammy Jindal, Vinay Pandit, Mahendra Singh Ashawat. Treatment and Management for patients with mild to severe Psoriasis: A review. Asian J. Pharm. Res. 2020; 10(4):286-292. Doi No 10. 5958/2231-5691.2020.00049.0

36) Rahamat Unissa, P. Mahesh Kumar, Gella Sunil. Psoriasis: A Comprehensive Review. Asian J. Res. Pharm. Sci. 2019; 9(1):29-38. DOI: 10.5958/2231-5659.2019.00005.5

37) Agar Pol, Vilasrao Kadam, Sujata Jagtap, Sampada Bhosale, Nita Pawar, Ravindra Gaikwad. Identification of Potential Flavonoids against the Spleen Tyrosine Kinase to Treat Psoriasis: In Silico approach. Asian Journal of Pharmacy and Technology. 2023; 13(2):84-0 Doi no 52711/2231-5691

38) Sanyam Sharma, Rahul Sharma, Kamya Goyal, Shammy Jindal. Potential of herbal treatment of Psoriasis: A Laconic Review. Doi no 10.5958/2231-5659.2021.00009.6

39) Shravan Kumar Dholi , D. Ruchitha Reddy Corticosteroid and rashes : A Comprehensive Review Asian Journal of Research in NephrologyMarch , 2024 page no. 45-48 issue 1 vol 7

40) Sakthi Priyadarsini S, Vani PB, Kumar PR. A Comparative Review on Conventional and Traditional medicine in the Treatment of Psoriasis. Research J. Pharm. and Tech. 2020; 13(11):5642-5646. **DOI:** 10.5958/0974-360X.2020.00983.X

41) Ritu Mukherjee A Comprehensive Review for Ruthenium(II) Complexes in Photodynamic Therapy, Asian Journal of Chemistry; Vol. 35, No. 11 (2023), 2595-2602 doi No. 10.14233/ajchem.2023.28555

42) Rahul Sabbu, Minnu Shaji Study on prescribing pattern for topical corticosteroid in outpatient department of dermatology at a tertiary care teaching Asian journal of pharmaceutical and health sciences nov 2021 page no. 2457-2461 Doi no. 10.5530/ajphs.2021.11.7

43) Aman Yadav, Dinesh Kumar Mishra, Pritesh Paliwal, Nadeem Farooqui, Arpit Gawshinde. Formulation and Evaluation of Polyherbal Antiaging Cream. Asian Journal of Pharmacy and Technology. 2021; 11(4):284-8. doi: 10.52711/2231-5713.2021.0004

44) www.google.com